Zobrazeno 1 - 3
of 3
pro vyhledávání: '"James Kochenderfer"'
Autor:
Kenneth Cornetta, Jing Yao, Kimberley House, Lisa Duffy, Prasad S. Adusumilli, Rachel Beyer, Claire Booth, Malcolm Brenner, Kevin Curran, Bambi Grilley, Helen Heslop, Christian S. Hinrichs, Rosandra N. Kaplan, Hans-Peter Kiem, James Kochenderfer, Donald B. Kohn, Sham Mailankody, Scott M. Norberg, Roisin E. O'Cearbhaill, Jennifer Pappas, Jae Park, Carlos Ramos, Antonio Ribas, Isabelle Rivière, Steven A. Rosenberg, Craig Sauter, Nirali N. Shah, Susan F. Slovin, Adrian Thrasher, David A. Williams, Tsai-Yu Lin
Publikováno v:
Molecular Therapy. 31:801-809
The clinical impact of any therapy requires the product be safe and effective. Gammaretroviral vectors pose several unique risks, including inadvertent exposure to replication competent retrovirus (RCR) that can arise during vector manufacture. The U
Autor:
Aiman J. Faruqi, John A. Ligon, Paul Borgman, Seth M. Steinberg, Toni Foley, Lauren Little, Crystal L. Mackall, Daniel W. Lee, Terry J. Fry, Haneen Shalabi, Jennifer Brudno, Bonnie Yates, Lekha Mikkilineni, James Kochenderfer, Nirali N. Shah
Publikováno v:
Blood Advances. 6:6040-6050
Cancer outcomes with chemotherapy are inferior in patients of minority racial/ethnic groups and those with obesity. Chimeric antigen receptor (CAR) T-cell therapy has transformed outcomes for relapsed/refractory hematologic malignancies, but whether
Autor:
Paul Borgman, John Ligon, Bonnie Yates, Haneen Shalabi, Toni Foley, Lauren Little, Jennifer Brudno, Lekha Mikkilineni, James Kochenderfer, Nirali N. Shah
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 31:PO-111
Introduction: Chimeric antigen receptor (CAR) T-cells have revolutionized therapies for B-cell malignancies. However, while ethnic and racial minorities or those with obesity represent medically underserved populations for whom cancer outcomes are wo